- Home
- LUD vs ACOG Comparison
LUD vs ACOG Comparison
Compare LUD & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUD
- ACOG
- Stock Information
- Founded
- LUD 2004
- ACOG 2000
- Country
- LUD Hong Kong
- ACOG Canada
- Employees
- LUD N/A
- ACOG N/A
- Industry
- LUD
- ACOG
- Sector
- LUD
- ACOG
- Exchange
- LUD NYSE
- ACOG Nasdaq
- Market Cap
- LUD 96.7M
- ACOG 80.3M
- IPO Year
- LUD 2025
- ACOG N/A
- Fundamental
- Price
- LUD $5.25
- ACOG $9.33
- Analyst Decision
- LUD
- ACOG Strong Buy
- Analyst Count
- LUD 0
- ACOG 1
- Target Price
- LUD N/A
- ACOG $20.00
- AVG Volume (30 Days)
- LUD 30.3K
- ACOG 76.9K
- Earning Date
- LUD 01-01-0001
- ACOG 08-14-2025
- Dividend Yield
- LUD N/A
- ACOG N/A
- EPS Growth
- LUD N/A
- ACOG N/A
- EPS
- LUD N/A
- ACOG N/A
- Revenue
- LUD $44,863,430.00
- ACOG $2,928,654.00
- Revenue This Year
- LUD N/A
- ACOG N/A
- Revenue Next Year
- LUD N/A
- ACOG N/A
- P/E Ratio
- LUD N/A
- ACOG N/A
- Revenue Growth
- LUD N/A
- ACOG N/A
- 52 Week Low
- LUD $3.40
- ACOG $3.75
- 52 Week High
- LUD $8.00
- ACOG $11.40
- Technical
- Relative Strength Index (RSI)
- LUD N/A
- ACOG N/A
- Support Level
- LUD N/A
- ACOG N/A
- Resistance Level
- LUD N/A
- ACOG N/A
- Average True Range (ATR)
- LUD 0.00
- ACOG 0.00
- MACD
- LUD 0.00
- ACOG 0.00
- Stochastic Oscillator
- LUD 0.00
- ACOG 0.00
About LUD LUDA TECHNOLOGY GROUP LIMITED
Luda Technology Group Ltd is a company that is principally engaged in the manufacture and sale of stainless steel and carbon steel flanges and fittings products and trading of steel pipes, valves, and other steel tubing products.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.